pharma · Hypertriglyceridemia
Mochida Pharmaceutical
Mochida Pharmaceutical Company,
Mochida Pharmaceutical Company is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertriglyceridemia. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent recor
USA HQ
42 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- USA
- Employees
- 42
- Programs
- 3
- Drugs
- 2
- Patents
- 0
Icosapent (MND-2119)
Phase 3 · small molecule · Hypertriglyceridemia
Icosapent (MND-2119) for Hypertriglyceridemia is a Phase 3 program (small_molecule) at Mochida Pharmaceutical Company, with 1 ClinicalTrials.gov record(s).
Internal code MND2119H31
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mochida Pharmaceutical Company,
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Hypertriglyceridemia
- Status
- completed
- Trials
- 1